Burning Rock Biotech (BNR) Liabilities and Shareholders Equity (2019 - 2026)

Burning Rock Biotech (BNR) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $113.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 3.27% year-over-year to $113.7 million; the TTM figure through Mar 2026 stood at $456.9 million (down 12.56% YoY), while the FY2025 annual figure was $117.3 million, down 3.28% from the prior year.
• Liabilities and Shareholders Equity came in at $113.7 million for Q1 2026 at Burning Rock Biotech, down from $115.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $332.1 million in Q1 2022, with the low at $113.5 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $170.1 million, with a median of $141.4 million recorded in 2024.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 37.62% in 2023 and retreated 3.27% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $223.2 million in 2022, then plunged by 35.29% to $144.4 million in 2023, then retreated by 14.67% to $123.2 million in 2024, then fell by 6.15% to $115.7 million in 2025, then decreased by 1.67% to $113.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $113.7 million, $115.7 million, and $113.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.